Empery Asset Management, LP → Annovis Bio, Inc. ANVS

Stake: — Shares: — Class: Common Stock, $0.0001 par value per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 21/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: -9.0%

Passive Schedule 13G filer baseline
Elevated short days-to-cover (8.3 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 8.34

5,720,877 shares short · -3.0% vs prior

Other Filings by Empery Asset Management, LP

Filed	Form	Issuer	Stake	Shares
2026-10-15	SCHEDULE 13G	Dyadic International Inc.	—	—	view →
2026-10-15	SCHEDULE 13G	Femasys Inc.	—	—	view →
2026-10-13	SCHEDULE 13G	Outlook Therapeutics, Inc.	—	—	view →
2026-09-03	SCHEDULE 13D/A	Empery Digital Inc.	—	4,830,345	view →
2026-08-14	SCHEDULE 13D/A	Empery Digital Inc.	15.76%	4,330,345	view →
2026-01-05	SCHEDULE	Empery Digital Inc. EMPD	8.97%	3,030,345	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →